Human T cell lymphotropic virus-associated leukemia/lymphoma

Current Opinion in Oncology

Volumn 17, Issue 5, 2005, Pages 469-473

  Ratner, Lee ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Human T cell leukemia lymphoma; Lymphoma; T cell leukemia lymphoma

Indexed keywords

ALEMTUZUMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ARSENIC TRIOXIDE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; LAMIVUDINE PLUS ZIDOVUDINE; ONCOPROTEIN; PREDNISONE; RECOMBINANT ALPHA INTERFERON; RETINOID; TAX PROTEIN; VINCRISTINE; ZIDOVUDINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; MOLECULAR BIOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RETROVIRUS; REVIEW; SIDE EFFECT; T CELL LEUKEMIA; T CELL LYMPHOMA;

ANTI-RETROVIRAL AGENTS; ANTIBODIES; ANTINEOPLASTIC AGENTS; DELTARETROVIRUS ANTIBODIES; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; LYMPHOMA, T-CELL; PROGNOSIS; STEM CELL TRANSPLANTATION;

EID: 24044505750     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000174037.84903.fb     Document Type: Review

References (73)

1. Bazarbachi A, Ghez D, Lepelletier Y, et al. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol 2004; 5:664-672. This is an excellent recent review of treatment for ATLL.
2. Ratner L. Adult T cell leukemia lymphoma. Front Biosci 2004; 9:2852-2859.
3. Kannagi M, Harashima N, Kurihara K, et al. Adult T-cell leukemia: future prophylaxis and immunotherapy. Expert Rev Anticancer Ther 2004; 4:369-376.
4. Franchini G, Nicot C, Johnson JM. Seizing of T cells by human T-cell leukemia/lymphoma virus type 1. Adv Cancer Res 2003; 89:69-132.
5. Jeang K-T, Giam C-Z, Majone F, Aboud M. Life, death, and Tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. J Biol Chem 2004; 279:31991-31994. This is an excellent review of the Tax oncoprotein.
6. Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol 2001; 19:475-496.
7. Lu H, Pise-Masison CA, Linton R, et al. Tax relieves transcriptional repression by promoting histone deacetylase 1 release from the human T-cell leukemia virus type 1 long terminal repeat. J Virol 2004; 78:6735-6743.
8. Portis T, Harding JC, Ratner L. The contribution of NF kB activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 (HTLV-1) tax-induced tumors. Blood 2001; 98:1200-1208.
9. Robek MD, Ratner L. Immortalization of T-lymphocytes by human T-cell leukemia virus type 1 tax mutants with different trans-activating phenotypes. J Virol 1999; 73:4856-4865.
10. Sinha-Datta U, Horikawa I, Michishita E, et al. Transcriptional activation of hTERT through the NF-kappaB pathway in HTLV-I-transformed cells. Blood 2004; 104:2523-2531.
11. Jeong SJ, Radonovich M, Brady JN, Pise-Masison CA. HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity. Blood 2004; 104:1490-1497.
12. Suzuki T, Narita T, Uchida-Toita M, Yoshida M. Down-regulation of the INK4 family of cyclin-dependent kinase inhibitors by tax protein of HTLV-1 through two distinct mechanisms. Virology 1999; 259:384-391.
13. Chowdhury IH, Farhadi A, Wang XF, et al. Human T-cell leukemia virus type 1 Tax activates cyclin-dependent kinase inhibitor p21/Waf1/Cip1 expression through a p53-independent mechanism: Inhibition of cdk2. Int J Cancer 2003; 107:603-611.
14. Li J, Li H, Tsai MD. Direct binding of the N-terminus of HTLV-1 tax oncoprotein to cyclin-dependent kinase 4 is a dominant path to stimulate the kinase activity. Biochemistry 2003; 42:6921-6928.
15. Kehn K, Fuente CL, Strouss K, et al. The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation. Oncogene 2005; 20: 525-540.
16. Haller K, Wu Y, Derow E, et al. Physical interaction of human T-cell leukemia virus type 1 Tax with cyclin-dependent kinase 4 stimulates the phosphorylation of retinoblastoma protein. Mol Cell Biol 2002; 22:3327-3338.
17. Liu B, Hong S, Tang Z, et al. HTLV-I Tax directly binds the Cdc20-associated anaphase-promoting complex and activates it ahead of schedule. Proc Natl Acad Sci USA 2005; 102:63-68.
18. Jin D-Y, Spencer F, Jeang K-T. Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1. Cell 1998; 93:81-91.
19. Park HU, Jeong JH, Chung JH, Brady JN. Human T-cell leukemia virus type 1 Tax interacts with Chk1 and attenuates DNA-damage induced G2 arrest mediated by Chk1. Oncogene 2004; 23:4966-4974.
20. Yasunaga J, Taniguchi Y, Nosaka K, et al. Identification of aberrantly methylated genes in association with adult T-cell leukemia. Cancer Res 2004; 64: 6002-6009.
21. Yamaguchi T, Ohshima K, Karube K, et al. Clinicopathological features of cutaneous lesions of adult T-cell leukaemia/lymphoma. Br J Haematol 2005; 152:76-81.
22. Imaisumi Y, Iwanaga M, Tsukasaki K, et al. Natural course of HTLV-1 carriers with monoclonal proliferation of T lymphocytes ('pre-ATL') in a 20-year follow-up study. Blood 2005; 105:903-904. This is one of a very few studies examining the conversion of pre-ATLL to ATLL in vivo.
23. Lee TH, Chafets DM, Busch MP, Murphy EL. Quantitation of HTLV-I and II proviral load using real-time quantitative PCR with SYBR Green chemistry. Clin Virol 2004; 31:275-282.
24. Koga H, Imada K, Ueda M, et al. Identification of differentially expressed molecules in adult T-cell leukemia cells proliferating in vivo. Cancer Sci 2004; 95: 411-417.
25. delaFuente C, Santiago F, Deng L, et al. Gene expression profile of HIV-1 Tat expressing cells: a close interplay between proliferative and differentiation signals. BMC Biochemistry 2002; 3:14.
26. Harhaj EW, Good L, Xiao G, Sun SC. Gene expression profiles in HTLV-I-immortalized T cells: deregulated expression of genes involved in apoptosis regulation. Oncogene 1999; 18:1341-1349.
27. Kohno T, Moriuchi R, Katamine S, et al. Identification of genes associated with the progression of adult T cell leukemia (ATL). Jpn J Cancer Res 2000; 91: 1103-1110.
28. Ng PW, Iha H, Iwanaga Y, et al. Genome-wide expression changes induced by HTLV-1 Tax: evidence for MLK-3 mixed lineage kinase involvement in Tax-mediated NF-kappaB activation. Oncogene 2001; 20:4484-4496.
29. Besson C, Panelati G, Delaunay C, et al. Treatment of adult T-cell leukemia-lymphoma by CHOP followed by therapy with antinucleosides, alpha interferon and oral etoposide. Leuk Lymphoma 2002; 43:2275-2279.
30. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001; 113:375-382.
31. Tsukasaki K, Tobinai K, Shimoyama M, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol 2003; 77:164-170.
32. Tobinai K. Chemotherapy of ATL. In: Sugamura K, Uchiyama T, Matsuoka M, Kannagi M, editors. Two decades of adult T-cell leukemia and HTLV-I research. Vol 50. Karger Publishing Co, Basel; 2003. pp. 263-276.
33. Taguchi H, Kinoshita KI, Takatsuki K, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr 1996; 12:182-186.
34. Tsuda H, Takatsuki K, Ohno R, et al. Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy. Br J Cancer 1994; 70:771-774.
35. Matsushita K, Matsumoto T, Ohtsubo H, et al. Long-term maintenance combination chemotherapy with OPEC/MPEC (vincristine or methotrexate, prednisolone, etoposide, and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia/lymphoma. Leuk Lymphoma 1999; 36:67-75.
36. Gill PS, Harrington W, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995; 332:1744-1748.
37. Hermine O, Bouscary D, Gessain A, et al. Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 1995; 332: 1749-1751.
38. Dega H, Chosidow O, Charlotte F, et al. Unsuccessful association of zidovuine and interferon alpha for acute adult T-cell leukemia lymphoma. Dermatology 1999; 198:103-105.
39. Hermine O, Allard I, Levy V, et al. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 2002; 3:276-282.
40. Matutes E, Taylor GP, Cavenagh J, et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Hematol 2001; 113:779-784.
41. White JD, Wharfe G, Stewart DM, et al. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma 2001; 40:287-294.
42. Bazarbachi A, Hermine O. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J Acquir Immune Defic Syndr 1996; 13(Suppl 1):S186-S190.
43. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101:4653-4659.
44. Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99:2685-2693.
45. Tsukasaki K, Maeda T, Arimura K, et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. Bone Marrow Transplant 1999; 23:87-89.
46. Utsonomiya A, Miyazaki Y, Takasuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27:15-20.
47. Ishikawa T, Ichinohe T, Imada K, Uchiyama T. Allogeneic hematopoietic stem cell transplantation for ATL. In: Sugamura K, Uchiyama T, Matsuoka M, Kannagi M, editors. Two decades of adult T-cell leukemia and HTLV-I research. Vol 50. Karger Publishing Co, Basel; 2003. pp. 253-262.
48. Kami M, Hamaki T, Miyakoshi S, et al. Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. Br J Haematol 2003; 120:304-309.
49. Kishi Y, Kami M, Oki Y, et al. Successful bone marrow transplantation for adult T-cell leukemia from a donor with oligoclonal proliferation of T-cells infected with human T-cell lymphotropic virus. Leuk Lymphoma 2001; 42: 819-822.
50. Nakane M, Ohashi K, Sato Y, et al. Molecular remission in adult T cell leukemia after autologous CD34+ peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24:219-221.
51. Borg A, Yin JA, Johnson PR, et al. Successful treatment of HTLV-1-associated acute adult T-cell leukaemia lymphoma by allogeneic bone marrow transplantation. Br J Haematol 1996; 94:713-715.
52. Sobue R, Yamauchim T, Miyamura K, et al. Treatment of adult T cell leukemia with mega-dose cyclophosphamide and total body irradiation followed by allogeneic bone marrow transplantation. Bone Marrow Transplant 1987; 2:441-444.
53. Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 2005; 105:4143-145.
54. Harashima N, Kurihara K, Utsunomiya A, et al. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res 2004; 64:391-399.
55. Kobayashi H, Nagato T, Yanai M, et al. Recognition of adult T-cell leukemia/lymphoma cells by CD4+ helper T lymphocytes specific for human T-cell leukemia virus type I envelope protein. Clin Cancer Res 2004; 10:7053-7062.
56. Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA 2003; 100: 1891-1895.
57. Zhang M, Zhang Z, Garmestani K, et al. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia. Cancer Res 2004; 64:5825-5829.
58. Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 1995; 86:4063-4075.
59. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematoogic malignancies. J Clin Oncol 2000; 18:1622-1636.
60. Moura IC, Lepelletier Y, Arnulf B, et al. A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 2004; 103:1838-1845.
61. Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol 2002; 19(Suppl):S27-S32.
62. Harhaj EW, Harhaj NS, Grant C, et al. Human T cell leukemia virus type I Tax activates CD40 gene expression via the NF-kappa B pathway. Virology 2005; 333:145-158.
63. Kannagi M, Ohashi T, Harashima N, et al. Immunological risks of adult T-cell leukemia at primary HTLV-I infection. Trends Microbiol 2004; 12:346-352.
64. Nomura M, Ohashi T, Nishikawa K, et al. Repression of Tax expression is associated both with resistance of human T-cell leukemia virus type 1-infected T cells to killing by Tax-specific cytotoxic T lymphocytes and with impaired tumorigenicity in a rat model. J Virol 2004; 78:3827-3836.
65. Mahieux R, Hermine O. In vivo and in vitro treatment of HTLV-1 and HTLV-2 infected cells with arsenic trioxide and interferon-alpha. Leuk Lymphoma 2005; 46:347-355.
66. El-Sabban ME, Nasr R, Dbaibo G, et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with Tax down-regulation and reversal of NF-κB activation. Blood 2000; 96:2849-2855.
67. Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999; 93:278-283.
68. Nasr R, Rosenwald A, El-Sabban ME, et al. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood 2003; 101:4576-4582.
69. Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha Interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004; 5:130-134.
70. Mitra-Kaushik S, Harding J, Hess J, Ratner L. Effects of the proteasome inhibitor, PS-341, on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood 2004; 104:802-809.
71. Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002; 62:1083-1086.
72. Miyatake JI, Maeda Y. Inhibition of proliferation and CD25 down-regulation by retinoicacid in human adult T cell leukemia cells. Leukemia 1997; 11:401-407.
73. Darwiche N, Hatoum A, Dbaibo G, et al. N-(4-hydroxyphenyl)retinamide induces growth arrest and apoptosis in HTLV-I-transformed cells. Leukemia 2004; 18:607-615.